tetano
Editor, Senior Moderator
Immunol Cell Biol. 2015 Jul 2. doi: 10.1038/icb.2015.71. [Epub ahead of print]
[h=1]Reducing the impact of influenza-associated secondary pneumococcal infections.[/h] Mifsud EJ[SUP]1[/SUP], Tan A[SUP]1[/SUP], Short KR[SUP]1[/SUP], Brown LE[SUP]1[/SUP], Chua B[SUP]1[/SUP], Jackson DC[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] When administered prophylactically, we show that the TLR-2 agonist PEG-Pam[SUB]2[/SUB]Cys not only mediates potent anti-viral activity against influenza virus but also reduces the impact of secondary infections with Streptococcus pneumoniae (the pneumococcus) by reducing (i) pulmonary viral and bacterial burdens (ii) the levels of pro-inflammatory cytokines that normally accompany influenza and S.pneumoniae secondary infections and (iii) the vascular permeability of the pulmonary tract that can allow bacterial invasion of the blood in mice.We also show that an inactivated detergent-disrupted influenza virus vaccine formulated with the Pam[SUB]2[/SUB]Cys-based adjuvant R[SUB]4-[/SUB]Pam[SUB]2[/SUB]Cys provides the host with both immediate and long-term protection against secondary pneumococcal infections following influenza virus infection through innate and specific immune mechanisms respectively. Vaccinated animals generated influenza virus-specific immune responses that provided the host with long-term protection against influenza virus and its sequelae. This vaccine, which generates an immediate-response, provides an additional countermeasure which is ideal for use even in the midst of an influenza outbreak.Immunology and Cell Biology accepted article preview online, 02 July 2015. doi:10.1038/icb.2015.71.
PMID: 26134269 [PubMed - as supplied by publisher]
[h=1]Reducing the impact of influenza-associated secondary pneumococcal infections.[/h] Mifsud EJ[SUP]1[/SUP], Tan A[SUP]1[/SUP], Short KR[SUP]1[/SUP], Brown LE[SUP]1[/SUP], Chua B[SUP]1[/SUP], Jackson DC[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] When administered prophylactically, we show that the TLR-2 agonist PEG-Pam[SUB]2[/SUB]Cys not only mediates potent anti-viral activity against influenza virus but also reduces the impact of secondary infections with Streptococcus pneumoniae (the pneumococcus) by reducing (i) pulmonary viral and bacterial burdens (ii) the levels of pro-inflammatory cytokines that normally accompany influenza and S.pneumoniae secondary infections and (iii) the vascular permeability of the pulmonary tract that can allow bacterial invasion of the blood in mice.We also show that an inactivated detergent-disrupted influenza virus vaccine formulated with the Pam[SUB]2[/SUB]Cys-based adjuvant R[SUB]4-[/SUB]Pam[SUB]2[/SUB]Cys provides the host with both immediate and long-term protection against secondary pneumococcal infections following influenza virus infection through innate and specific immune mechanisms respectively. Vaccinated animals generated influenza virus-specific immune responses that provided the host with long-term protection against influenza virus and its sequelae. This vaccine, which generates an immediate-response, provides an additional countermeasure which is ideal for use even in the midst of an influenza outbreak.Immunology and Cell Biology accepted article preview online, 02 July 2015. doi:10.1038/icb.2015.71.
PMID: 26134269 [PubMed - as supplied by publisher]